208 related articles for article (PubMed ID: 23977763)
1. High-dose interleukin-2: is it still indicated for melanoma and RCC in an era of targeted therapies?
Amin A; White RL
Oncology (Williston Park); 2013 Jul; 27(7):680-91. PubMed ID: 23977763
[TBL] [Abstract][Full Text] [Related]
2. Is IL-2 still indicated for melanoma and RCC? What a question to ask!
Hamid O
Oncology (Williston Park); 2013 Jul; 27(7):695, 701. PubMed ID: 23977765
[No Abstract] [Full Text] [Related]
3. Weighing the evidence for immune therapy and targeted therapy in renal cancer and melanoma.
Dorff TB; Wong MK
Oncology (Williston Park); 2013 Jul; 27(7):691-2, 694. PubMed ID: 23977764
[No Abstract] [Full Text] [Related]
4. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma.
Hughes T; Klairmont M; Broucek J; Iodice G; Basu S; Kaufman HL
Cancer Immunol Immunother; 2015 Apr; 64(4):459-65. PubMed ID: 25603775
[TBL] [Abstract][Full Text] [Related]
5. Clinical and safety profile of high-dose interleukin-2 treatment in elderly patients with metastatic melanoma and renal cell carcinoma.
Clark JM; Kelley B; Titze J; Fung H; Maciejewski J; Nathan S; Rich E; Basu S; Kaufman HL
Oncology; 2013; 84(2):123-6. PubMed ID: 23235386
[TBL] [Abstract][Full Text] [Related]
6. Interleukin 2 in cancer therapy.
Antony GK; Dudek AZ
Curr Med Chem; 2010; 17(29):3297-302. PubMed ID: 20712575
[TBL] [Abstract][Full Text] [Related]
7. Treatment of metastatic renal cell carcinoma.
Reeves DJ; Liu CY
Cancer Chemother Pharmacol; 2009 Jun; 64(1):11-25. PubMed ID: 19343348
[TBL] [Abstract][Full Text] [Related]
8. High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.
Dutcher JP
Oncology (Williston Park); 2011 Apr; 25(5):427-8. PubMed ID: 21710841
[No Abstract] [Full Text] [Related]
9. Interleukin-2: clinical applications.
Atkins MB
Semin Oncol; 2002 Jun; 29(3 Suppl 7):12-7. PubMed ID: 12068383
[TBL] [Abstract][Full Text] [Related]
10. Cytokine therapy: a standard of care for metastatic renal cell carcinoma?
Hutson TE; Quinn DI
Clin Genitourin Cancer; 2005 Dec; 4(3):181-6. PubMed ID: 16425986
[TBL] [Abstract][Full Text] [Related]
11. High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.
Marabondo S; Kaufman HL
Expert Opin Drug Saf; 2017 Dec; 16(12):1347-1357. PubMed ID: 28929820
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 for the treatment of melanoma.
Tarhini AA; Agarwala SS
Curr Opin Investig Drugs; 2005 Dec; 6(12):1234-9. PubMed ID: 16370388
[TBL] [Abstract][Full Text] [Related]
13. Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Alva A; Daniels GA; Wong MK; Kaufman HL; Morse MA; McDermott DF; Clark JI; Agarwala SS; Miletello G; Logan TF; Hauke RJ; Curti B; Kirkwood JM; Gonzalez R; Amin A; Fishman M; Agarwal N; Lowder JN; Hua H; Aung S; Dutcher JP
Cancer Immunol Immunother; 2016 Dec; 65(12):1533-1544. PubMed ID: 27714434
[TBL] [Abstract][Full Text] [Related]
14. Successes and limitations of targeted therapies in renal cell carcinoma.
Pracht M; Berthold D
Prog Tumor Res; 2014; 41():98-112. PubMed ID: 24727990
[TBL] [Abstract][Full Text] [Related]
15. What to do with IL-2?
Dillman RO
Cancer Biother Radiopharm; 1999 Dec; 14(6):423-34. PubMed ID: 10850329
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 therapy of metastatic renal cell carcinoma--predictors of response.
McDermott DF; Atkins MB
Semin Oncol; 2006 Oct; 33(5):583-7. PubMed ID: 17045087
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers of therapeutic response in melanoma and renal cell carcinoma: potential inroads to improved immunotherapy.
Kirkwood JM; Tarhini AA
J Clin Oncol; 2009 Jun; 27(16):2583-5. PubMed ID: 19364958
[No Abstract] [Full Text] [Related]
18. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
[TBL] [Abstract][Full Text] [Related]
19. Toxicity and activity of a twice daily high-dose bolus interleukin 2 regimen in patients with metastatic melanoma and metastatic renal cell cancer.
Acquavella N; Kluger H; Rhee J; Farber L; Tara H; Ariyan S; Narayan D; Kelly W; Sznol M
J Immunother; 2008; 31(6):569-76. PubMed ID: 18528297
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-21: updated review of Phase I and II clinical trials in metastatic renal cell carcinoma, metastatic melanoma and relapsed/refractory indolent non-Hodgkin's lymphoma.
Hashmi MH; Van Veldhuizen PJ
Expert Opin Biol Ther; 2010 May; 10(5):807-17. PubMed ID: 20384523
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
